Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (10313)	2/7/2004 6:01:57 PM
From: Icebrg	Read Replies (2) \| Respond to of 52153

Aphton One question. Why do you think the trial was designed the way it was? In some respects it was fairly ambitious. With the number of sites enrolled in both Europe and the US. On the other hand - to run this without a control arm doesn't make much sense. What was Aphton looking for and do you think their questions were answered? If they believe that their product gives a benefit it would IMHO have been much easier to run a conventional two-arm study with median survival time as the primary endpoint. Erik